Suchergebnisse - (Standardsuche:Dexamethasone OR corticosteroid)

1

Clinical review report : (Novartis Pharmaceuticals Canada Inc.) : indication: asthma maintenance, adultsIndacaterol acetate-glycopyrronium bromide-mometasone furoate (Enerzair Breezhaler)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, January 2021

CADTH common drug review

Version: Final (with redactions).

2

Pharmacoeconomic report : (Novartis Pharmaceuticals Canada Inc.) : indication: asthma maintenance, adultsIndacaterol acetate-glycopyrronium bromide-mometasone furoate (Enerzair Breezhaler)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, January 2021

CADTH common drug review

Version: Final (with redactions).

3

Pharmacoeconomic review report : (Novartis Pharmaceuticals Canada Inc.) : indication : once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airway diseaseIndacaterol/mometasone furoate (Atectura Breezhaler)

Erschienen: Ottawa, Canadian Agency for Drugs and Technologies in Health, January 2021

CADTH common drug review

Version: Final (with redactions).

4

CADTH Canadian Drug Expert Committee recommendation : indication: asthma maintenance (adults, children aged 12 or older)Indacaterol/Mometasone Furoate (Atectura Breezhaler -- Novartis Pharmaceuticals Canada Inc.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, November 2020

CADTH common drug review

Verion: 1.0

5

CADTH Canadian Drug Expert Committee recommendation : indication: asthma maintenance, adultsIndacaterol/glycopyrronium/mometasone furoate (Enerzair Breezhaler -- Novartis Pharmaceuticals Canada Inc.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, November 2020

CADTH common drug review

Verion: 1.0

6

Advances in asthma : pathophysiology, diagnosis and treatment

Erschienen: Singapore, Springer, [2019]

Respiratory disease series: diagnostic tools and disease managements

von Yokoyama, A.

7

Pharmacoeconomic review report : indication : for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and olderFluticasone propionate (Aermony Respiclick) (Teva Canada Innovation)

Erschienen: Ottawa (ON), CADTH, January 2019

CADTH common drug review

Final (with redactions).

8

Advances in Asthma : Pathophysiology, Diagnosis and Treatment

Erschienen: Singapore, Springer, 2018

Respiratory Disease Series: Diagnostic Tools and Disease Managements Ser.

von Yokoyama, A.

9

Pharmacoeconomic review report : indication : an add-on maintenance treatment of adult patients with severe eosinophilic asthmaBenralizumab (Fasenra) (AstraZeneca Canada Inc.)

Erschienen: Ottawa (ON), CADTH, August 2018

CADTH common drug review

Final with redactions.

10

CADTH Canadian drug expert committee recommendation : indication : severe eosinophilic asthmaBenralizumab (Fasenra -- Astrazeneca Canada Inc.)

Erschienen: Ottawa (ON), CADTH, August 2018

CADTH common drug review

Final.

Filter & Sortierung